3 ms·
disclaimer, I work on cancer drugs so I can shed some light on your question. > a very high percentage of people would opt for a potentially fatal, completely
by ekianjo 13y ago
disclaimer, I work on cancer drugs so I can shed some light on your question.
> a very high percentage of people would opt for a potentially fatal, completely untested course of action as opposed to imminent death. So who gets to try these treatments, who tells dying patients they are not allowed them, and is there a black market or large amounts of money changing hands for experimental procedures?
First, for many cancers you do not die of an imminent death. Sometimes it can take 5 to 10 years to die from Cancer.Unless you are affected by a cancer where no treatent is available, there are usually multiple courses of treatments you can follow before being out of options.So patients are actually trying existing methods before jumping to new treatments. New treatments are only available in small quantities and there are strict criteria for the selection of patients. And in Oncology actually we already give the chance for patients to try new drugs as soon as the safety evaluation begins, whereas for other therapies we go through healthy volunteers first. For a patient there is not much incentive to join Ph1 since the efficacy is not proven and there is a dose escalation method so you may not get the efficacy dose even if you enter the trial. Besides, there are safety risks involved and some patients die in Ph1. So every patient signs an informed consent that they are aware of the risks involved.
As for the hundred of thousands of patients, the companies cannot support them for many reasons: as mentioned, the drugs are only manufactured in small quantities in early stages and it takes years to scale up the process. Second, clinical trials cost a lot of money, and the more you have patients the more it costs. So you dont recruit more patients than what you need to do your evaluation. This being said, most pharma companies continue providing drug even after the trial is completed to patients who see efficacy with it. Third, the larger the trial, the longer the enrollment time and the longer it takes to get the results back and therefore the longer it takes before the drugs reach the market.